Human medicines European public assessment report (EPAR): Rybrevant, amivantamab, Date of authorisation: 09/12/2021, Revision: 10, Status: Authorised

List of medicinal products under additional monitoring

List of medicinal products under additional monitoring

EU Regulatory System Incident Management Plan for Medicines for Human Use

Business process description for pharmacovigilance

Lenalidomide Mylan

What we publish on medicines and when

EMEA-001260-PIP01-11-M03

EMEA-002996-PIP01-21

Opinion/decision on a Paediatric investigation plan (PIP): Gavreto, pralsetinib, decision type: P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s), therapeutic area: Oncology, PIP number: P/0271/2021